Pfizer's Phase 3 data lifts Litfulo as promising vitiligo therapy

SentiSense · Published · Updated

Pfizer presented detailed results from its TRANQUILLO and TRANQUILLO 2 Phase 3 trials at the EADV Congress, showing that Litfulo (ritlecitinib), alrea...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis